^
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab + paclitaxel
Sensitive
:
C3
ESMO-BC 2021 - 1wk
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + TAK-228
Sensitive
:
C2
Breast Cancer Res Treat - 3wk
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive
:
C3
NPJ Breast Cancer - 3wk
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive
:
A1
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive
:
A1
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive
:
B
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
B
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant
:
B
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
B
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive
:
C2
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive
:
C2
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive
:
C3
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive
:
C3
CDK6 overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant
:
C3
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant
:
C3
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive
:
C3
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant
:
C3
CCNE1 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant
:
C3
CDK2 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant
:
C3
CCND1 amplification
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our